Setting | Investigator | Case-fatality rate |
Community | ||
Finland | Jokinen et al3 | 4% overall; 11% ≥60 years; 0.6% 15–59 years; highest men ≥60 years |
France | Fantin et al78 | 3.8% |
Community and hospital | ||
Spain | Almirall et al69 | 5.0% |
Italy | Viegi et al71 | 6.0%; hospitalised > outpatients |
Spain | Vila-Corcoles et al8 | 12.7% overall; 2% outpatients, 15% hospitalised |
Spain | Ochoa-Gondar et al70 * | 12.7%; increased with age |
Germany | Kothe et al9 | 6.3% overall; 2.2% <65 years, 10.3% ≥65 years |
Hospital | ||
England | Venkatesan et al50 | 33% |
Denmark | Nielsen et al77 | 17%, all >65 years (range 21–92 years) |
Spain | Rello et al44 | 22.4% |
Denmark | Ostergaard and Andersen39 | 6.3% |
The Netherlands | Bohte et al13 | 8% |
Spain | Pallares et al63 | 28% |
Switzerland | Janssens et al79 | 14% |
Germany | Holtermann et al80 | 31% |
Spain | Ewig et al64 | 11% immunocompetent; 9% immunosuppressed15% antibiotic-resistant; 6% antibiotic-sensitive strains |
France | Georges et al22 | 27.5% |
Italy | Logroscino et al81 | 2.8%; mortality increased with disease severity according to Fine risk categories |
Spain | Arancibia et al82 | 43% |
Spain | Monge et al75 | 2.7% <65 years; 11.6% ≥65 years |
Switzerland | Garbino et al21 | 8% |
France | Jehl et al58 | 16.3% |
Spain | Celis et al | 6% |
Spain | Nunez Fernandez et al61 | Age <60 years: 6.6%; age ≥60 years: 15.7%; PSI score associated >140 |
Portugal | Froes4 | 14.0%; increased with age |
Spain | Aspa et al67 | 14.4% |
The Netherlands | Braun et al12 | 17.8% |
Spain | Falco et al66 | 9.9–13.7%, related to antibiotic susceptibility |
Italy | Rossi et al24 | Overall: 11.2%; age ≥65 years: 13.8% |
Spain | Martinez-Moragon et al37 | 11%; Fine severity score associated |
Spain | Menendez et al83 | 5.6% |
France | Paganin et al42 | 43% |
Spain | Roson et al46 | 4% early treatment response; 27% early treatment failure |
France | Bonnard et al59 | 32%; associated with PSI scores of 90 and 130 |
Ireland | Foley et al84 | 2% <65 years; 11.5% >65 years |
Spain | Valles et al62 | 7% |
England and Wales | Melegaro et al73 | Range: 1–20% age related |
England | Trotter et al5 | Range: 24.8–28.2% related to year (1997–1998 to 2004–2005) |
ICU | ||
England | Alkhayer et al85 | 28% |
Spain | Torres et al49 | 22% |
UK | BTS Research Committee14 | 48% |
France (ICU and ID unit) | Leroy et al35 | 28.5% |
France | Moine et al38 | 35% |
France | Leroy et al86 | 19% <65 years; 30% ≥65 years (CAP attributable) |
Spain | Rello et al87 | 11.1–44.7% related to antibiotic regimen |
Spain | Rello et al43 | 23.5%; age associated |
BTS, British Thoracic Society; CAP, community-acquired pneumonia; ICU, intensive care unit; ID, infectious disease; PSI, pneumonia severity index.
↵* Includes ICU.